HomeUpdate on the Allerject recall: CSACI statement, EpiPen Availability, FAQs and more

Update on the Allerject recall: CSACI statement, EpiPen Availability, FAQs and more

October 30, 2015

As you may know by now, Sanofi issued a voluntary recall of all Allerject products earlier this week. Food Allergy Canada is concerned about this issue, and we know that you are, too. Please share this link with anyone you know who may be affected.

Since Sanofi’s release was issued, we have been communicating with Sanofi, Health Canada, the Canadian Society of Allergy and Clinical Immunology (CSACI), Pfizer and many others to try to spread the word as quickly as possible and to provide updates as they become available. We have also shared community concerns and experiences with Health Canada and the company, too.

For your information, we have included below a statement from the CSACI and a link to Pfizer’s information about the availability of EpiPens. We have also provided links to Health Canada’s advisory and the Allerject website, where you can see their release and FAQs.

  • October 30, 2015 – Statement by the CSACI on Allerject Recall: “As you are likely aware, Sanofi Canada has voluntarily recalled all lots of Allerject epinephrine auto injector devices, due to concerns about potentially inaccurate dosing. This recall includes all Allerject devices that have been dispensed in Canada (both 0.15 mg and 0.3 mg strengths). Plans are in place for patients to exchange their Allerject devices for replacement EpiPen devices at their local pharmacy, at no cost to the patient. No prescription is needed to make this exchange. Due to the large demand and limited EpiPen supply, it may take some time for this exchange to be completed. Pfizer Canada, the distributor of EpiPen, is working to increase EpiPen supply quickly. In the meantime, while families are waiting for their EpiPen replacement device, they should not hesitate to use their Allerject in the event of anaphylaxis, following the directions they have been previously given by their physicians.”
  • Pfizer Statement about EpiPen® Availability
  •  Allerject’s website with press release and FAQs
  • Health Canada’s Notice – Sanofi recalls all lots of Allerject (0.15 mg/0.15 mL and 0.3 mg/0.3 mL strengths of epinephrine auto-injectors)

We encourage you to contact Sanofi directly with your questions or concerns about this voluntary product recall – contact the Allerject Call Center at 1-855-405-4321.

Please keep us updated about your experiences on our Facebook page or by emailing us at info@foodallergycanada.ca.

We will provide more details as they become available.



Tags: , ,